The flavonols quercetin and 3,4-dihydroxyflavonol reduce platelet function and delay thrombus formation in a model of type 1 diabetes

Diabetes and Vascular Disease Research

Volumn 11, Issue 3, 2014, Pages 174-181

  Mosawy, Sapha ^a   Jackson, Denise E ^a   Woodman, Owen L ^a   Linden, Matthew D ^a,b  

^a RMIT UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

3 4 dihydroxyflavonol; Diabetes; flavonol; platelet; quercetin; thrombosis

Indexed keywords

3',4' DIHYDROXYFLAVONOL; CHLORIDE; FLAVONOL DERIVATIVE; GLUCOSE; QUERCETIN; UNCLASSIFIED DRUG; 3',4'-DIHYDROXYFLAVONOL; ANTIOXIDANT; FERRIC CHLORIDE; FERRIC ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; BLOOD FLOW; CONTROLLED STUDY; EXOCYTOSIS; FERRIC CHLORIDE-INDUCED THROMBOSIS; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; RECORDING; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; THROMBOCYTE POOR PLASMA; TREATMENT OUTCOME; ANIMAL; C57BL MOUSE; CAROTID ARTERY; CAROTID ARTERY INJURY; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; LASER DOPPLER FLOWMETRY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; TOXICITY;

ANIMALS; ANTIOXIDANTS; BLOOD PLATELETS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CHLORIDES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; EXOCYTOSIS; FERRIC COMPOUNDS; FLAVONOLS; LASER-DOPPLER FLOWMETRY; MICE; MICE, INBRED C57BL; PLATELET ACTIVATION; PLATELET AGGREGATION; QUERCETIN; THROMBOSIS;

EID: 84900301629     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114524234     Document Type: Article

References (49)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 ; 87: 4-14
2. Colagiuri S, Brnabic A, Gomez M, et al DiabCost Australia Type 1: Assessing the burden of Type 1 Diabetes in Australia. Canberra: Diabetes Australia ; 2009 :
3. Colagiuri S, Colagiuri R, Conway B, et al DiabCost Australia: Assessing the burden of Type 2 Diabetes in Australia. Canberra: Diabetes Australia ; 2003 :
4. Chait A, Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia?. J Lipid Res. 2009 ; 50: S335 - S339
5. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010 ; 121: 2694-2701
6. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol. 1989 ; 14: 49-57
7. Singer DE, Moulton AW, Nathan DM. Diabetic myocardial infarction. Interaction of diabetes with other preinfarction risk factors. Diabetes. 1989 ; 38: 350-357
8. Balasubramaniam K, Viswanathan GN, Marshall SM, et al. Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract. 2012 ; 2012: 909154
9. Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med. 2007 ; 17: 48-54
10. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999 ; 48: 937-942
11. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007 ; 116: 151-157
12. Ajjan RA. Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. Diab Vasc Dis Res. 2012 ; 9: 243-244
13. Linden MD, Tran HA. Overcoming aspirin treatment failure in diabetes. Crit Rev Clin Lab Sci. 2012 ; 49: 183-198
14. Holt RR, Actis-Goretta L, Momma TY, et al. Dietary flavonols and platelet reactivity. J Cardiovasc Pharmacol. 2006 ; 47: S187 - S196
15. Herrmann K. Flavonols and flavones in food plants: a review. Int J Food Sci Tech. 1976 ; 11: 433-448
16. Geleijnse JM, Launer LJ, Van der Kuip DA, et al. Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study. Am J Clin Nutr. 2002 ; 75: 880-886
17. Chong MF, Macdonald R, Lovegrove JA. Fruit polyphenols and CVD risk: a review of human intervention studies. Br J Nutr. 2010 ; 104: S28 - S39
18. Vitseva O, Varghese S, Chakrabarti S, et al. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates. J Cardiovasc Pharmacol. 2005 ; 46: 445-451
19. Freedman JE, Parker C, Li L, et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation. 2001 ; 103: 2792-2798
20. Briggs WH, Folts JD, Osman HE, et al. Administration of raw onion inhibits platelet-mediated thrombosis in dogs. J Nutr. 2001 ; 131: 2619-2622
21. Aherne SA, O'Brien NM. Dietary flavonols: chemistry, food content, and metabolism. Nutrition. 2002 ; 18: 75-81
22. Machha A, Achike FI, Mustafa AM, et al. Quercetin, a flavonoid antioxidant, modulates endothelium-derived nitric oxide bioavailability in diabetic rat aortas. Nitric Oxide. 2007 ; 16: 442-447
23. Anjaneyulu M, Chopra K. Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol. 2004 ; 31: 244-248
24. Coskun O, Kanter M, Korkmaz A, et al. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and I-cell damage in rat pancreas. Pharmacol Res. 2005 ; 51: 117-123
25. Vessal M, Hemmati M, Vasei M. Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. Comp Biochem Physiol C Toxicol Pharmacol. 2003 ; 135: 357-364
26. Woodman OL, Malakul W. 3,4-Dihydroxyflavonol prevents diabetes-induced endothelial dysfunction in rat aorta. Life Sci. 2009 ; 85: 54-59
27. Leo CH, Hart JL, Woodman OL. 3,4-Dihydroxyflavonol reduces superoxide and improves nitric oxide function in diabetic rat mesenteric arteries. PLoS One. 2011 ; 6: e20813
28. Leo CH, Hart JL, Woodman OL. 3,4-Dihydroxyflavonol restores endothelium-dependent relaxation in small mesenteric artery from rats with type 1 and type 2 diabetes. Eur J Pharmacol. 2011 ; 659: 193-198
29. Mosawy S, Jackson DE, Woodman OL, et al. Inhibition of platelet-mediated arterial thrombosis and platelet granule exocytosis by 3,4-dihydroxyflavonol and quercetin. Platelets. 2013 ; 24: 594-604
30. Mosawy S, Jackson DE, Woodman OL, et al. Treatment with quercetin and 3,4-dihydroxyflavonol inhibits platelet function and reduces thrombus formation in vivo. J Thromb Thrombolysis. 2013 ; 36: 50-57
31. Westermann D, Rutschow S, Van Linthout S, et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia. 2006 ; 49: 2507-2513
32. Crawford GL, Hart GW, Whiteheart SW. Murine platelets are not regulated by O-linked beta-N-acetylglucosamine. Arch Biochem Biophys. 2008 ; 474: 220-224
33. Wall JE, Buijs-Wilts M, Arnold JT, et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol. 1995 ; 89: 380-385
34. Linden MD, Frelinger AL, Barnard MR, et al. Application of flow cytometry to platelet disorders. Semin Thromb Hemost. 2004 ; 30: 501-511
35. Akkerman JWN, Gorter G, Kloprogge E. Kinetic analysis of alpha-granule secretion by platelets. A methodological report. Thromb Res. 1982 ; 27: 59-64
36. Kajita K, Ishizuka T, Miura A, et al. Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control. Platelets. 2001 ; 12: 343-351
37. Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol. 2001 ; 280: H1480 - H1489
38. Badimón L, Vilahur G, Padró T, et al. Lipoproteins, platelets and atherothrombosis. Rev Esp Cardiol (English Edition). 2009 ; 62: 1161-1178
39. Anderson GM, Hall LM, Yang JX, et al. Platelet dense granule release reaction monitored by high-performance liquid chromatography-fluorometric determination of endogenous serotonin. Anal Biochem. 1992 ; 206: 64-67
40. Leo CH, Joshi A, Woodman OL. Short term type 1 diabetes alters the mechanism of endothelium-dependent relaxation in the rat carotid artery. Am J Physiol Heart Circ Physiol. 2010 ; 299: H502 - H511
41. Gerrard JM, Stuart MJ, Rao GH, et al. Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J Lab Clin Med. 1980 ; 95: 950-958
42. Shukla SD, Kansra SV, Reddy MA, et al. Platelets from diabetic pigs exhibit hypersensitivity to thrombin. Comp Med. 2008 ; 58: 481-484
43. Dunbar JC, Reinholt L, Henry RL, et al. Platelet aggregation and disaggregation in the streptozotocin induced diabetic rat: the effect of sympathetic inhibition. Diabetes Res Clin Pract. 1990 ; 9: 265-272
44. Ajay M, Achike FI, Mustafa AM, et al. Effect of quercetin on altered vascular reactivity in aortas isolated from streptozotocin-induced diabetic rats. Diabetes Res Clin Pract. 2006 ; 73: 1-7
45. Ikizler M, Erkasap N, Dernek S, et al. Dietary polyphenol quercetin protects rat hearts during reperfusion: enhanced antioxidant capacity with chronic treatment. Anadolu Kardiyol Derg. 2007 ; 7: 404-410
46. Bartekova M, Carnicka S, Pancza D, et al. Acute treatment with polyphenol quercetin improves postischemic recovery of isolated perfused rat hearts after global ischemia. Can J Physiol Pharmacol. 2010 ; 88: 465-471
47. Sanders RA, Rauscher FM, Watkins JB. Effects of quercetin on antioxidant defense in streptozotocin-induced diabetic rats. J Biochem Mol Toxicol. 2001 ; 15: 143-149
48. Coldiron AD, Sanders RA, Watkins JB. Effects of combined quercetin and coenzyme Q(10) treatment on oxidative stress in normal and diabetic rats. J Biochem Mol Toxicol. 2002 ; 16: 197-202
49. Cheng IF, Breen K. On the ability of four flavonoids, baicilein, luteolin, naringenin, and quercetin, to suppress the Fenton reaction of the iron-ATP complex. Biometals. 2000 ; 13: 77-83